129 Using a scenario approach to assess for the current and future demand of immunoglobulins Supplementary Table 1 References 1. Ehsani-Chimeh N, Marinkovich MP. Practice and Educational Gaps in Blistering Disease. Dermatol Clin 2016; 34(3): 251-6. 2. Enk AH, Hadaschik EN, Eming R, Fierlbeck G. European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology. 2016. 3. Forbat E, Ali FR, Al-Niaimi F. Intravenous immunoglobulins in dermatology. Part 1: biological mechanisms and methods of administration. Clin Exp Dermatol 2018; 43(5): 513-7. 4. Forbat E, Ali FR, Al-Niaimi F. Intravenous immunoglobulins in dermatology. Part 2: clinical indications and outcomes. Clin Exp Dermatol 2018; 43(6): 659-66. 5. Heelan K, Hassan S, Bannon G, et al. Cost and Resource Use of Pemphigus and Pemphigoid Disorders Pre- and Post-Rituximab. J Cutan Med Surg 2015; 19(3): 274-82. 6. Thomas RM, Colon A, Motaparthi K. Rituximab in autoimmune pemphigoid diseases: Indications, optimized regimens, and practice gaps. Clin Dermatol 2020; 38(3): 384-96. 7. Aringer M, Burkhardt H, Burmester GR, et al. Current state of evidence on ‘off-label’ therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report. Lupus; 2012. p. 386-401. 8. Abboud H, Probasco JC, Irani S, et al. Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. Journal of neurology, neurosurgery, and psychiatry 2021; 92(7): 75768. 9. Goddard S, Hughes D, Diwakar L, Graham J. Impact of stopping long-term immunoglobulin therapy in haematological secondary antibody deficiency. British Journal of Haematology 2020; 189 (Supplement 1): 91. 10. Khellaf M, Michel M, Quittet P, et al. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood 2011; 118(16): 433845. 11. Na IK, Buckland M, Agostini C, et al. Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies. Eur J Haematol 2019. 12. Nahirniak S, Hume HA. Guidelines for the use of immunoglobulin therapy for primary immune deficiency and solid organ transplantation. Transfus Med Rev 2010; 24 Suppl 1: S1-6. 13. Nierhaus A, Berlot G, Kindgen-Milles D, Müller E, Girardis M. Best-practice IgM- and IgA-enriched immunoglobulin use in patients with sepsis. Annals of intensive care 2020; 10(1): 132. 14. Michel M, Adoue D, Cheze S, et al. French observatory of adult’ chronic immune thrombocytopenia (ITP) treated by thrombopoietin receptor agonists (TPO-RAS). Blood 2015; Conference(var.pagings): 2250. 15. Reiser M, Borte M, Huscher D, et al. Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS study. Eur J Haematol 2017; 99(2): 169-77. 16. Soares MO, Welton NJ, Harrison DA, et al. Intravenous immunoglobulin for severe sepsis and septic shock: clinical effectiveness, cost-effectiveness and value of a further randomised controlled trial. Crit Care 2014; 18(6): 649. 17. Wasserman RL. Clinical Practice Experience with HyQvia in Adults Using Alternative Dosing Regimens and Pediatric Patients: A Retrospective Study. Advances in therapy 2020; 37(4): 1536-49. 18. Wiesik-Szewczyk E, Sołdacki D, Paczek L, Jahnz-Różyk K. Facilitated Subcutaneous Immunoglobulin Replacement Therapy in Clinical Practice: A Two Center, Long-Term Retrospective Observation in Adults With Primary Immunodeficiencies. Front Immunol 2020; 11: 981. 19. Absoud M, Lim MJ. Intravenous immunoglobulin in paediatric neurology: evaluating effective usage and outcomes. Developmental medicine and child neurology 2016; 58(11): 1105-6. 20. Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2013; (12): CD001797. 21. Furlan JC, Barth D, Barnett C, Bril V. Cost-minimization analysis comparing intravenous immunoglobulin with
RkJQdWJsaXNoZXIy MTk4NDMw